ArticleJournal of imaging informatics in medicine2026
Prediction of Future Risk of Moderate to Severe Kidney Function Loss Using a Deep Learning Model-Enabled Chest Radiography.
Article in Journal of imaging informatics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) remains a major public health concern, requiring better predictive models for early intervention. This study evaluates a deep learning model (DLM) that utilizes raw chest X-ray (CXR) data to predict moderate to severe kidney function decline. We analyzed data from 79,219 patients with an estimated Glomerular Filtration Rate (eGFR) between 65 and 120, segmented into development (n = 37,983), tuning (n = 15,346), internal validation (n = 14,113), and external validation (n = 11,777) sets. Our DLM, pretrained on CXR-report pairs, was fine-tuned with the development set. We retrospectively examined data spanning April 2011 to February 2022, with a 5-year maximum follow-up. Primary and secondary endpoints included CKD stage 3b progression, ESRD/dialysis, and mortality. The overall concordance index (C-index) values for the internal and external validation sets were 0.903 (95% CI, 0.885-0.922) and 0.851 (95% CI, 0.819-0.883), respectively. In these sets, the incidences of progression to CKD stage 3b at 5 years were 19.2% and 13.4% in the high-risk group, significantly higher than those in the median-risk (5.9% and 5.1%) and low-risk groups (0.9% and 0.9%), respectively. The sex, age, and eGFR-adjusted hazard ratios (HR) for the high-risk group compared to the low-risk group were 16.88 (95% CI, 10.84-26.28) and 7.77 (95% CI, 4.77-12.64), respectively. The high-risk group also exhibited higher probabilities of progressing to ESRD/dialysis or experiencing mortality compared to the low-risk group. Further analysis revealed that the high-risk group compared to the low/median-risk group had a higher prevalence of complications and abnormal blood/urine markers. Our findings demonstrate that a DLM utilizing CXR can effectively predict CKD stage 3b progression, offering a potential tool for early intervention in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.